NCT04412252View on ClinicalTrials.gov

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 6, 2020

Primary Completion Date

September 16, 2020

Study Completion Date

October 18, 2020

Conditions
COVID-19
Interventions
DRUG

Tofacitinib

10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days

OTHER

Placebo

Tofacitinib-matching placebo administered as tablets or solution taken orally twice daily for 14 days

Trial Locations (6)

44106

University Hospitals Cleveland Medical Center, Cleveland

52242

University of Iowa Hospitals & Clinics Investigational Drug Services, Iowa City

University of Iowa, Iowa City

71103

LSUHSC-Shreveport, Shreveport

Ochsner LSU Health Shreveport Academic Medical Center, Shreveport

06102

Hartford Hospital (HH), Hartford

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04412252 - Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy | Biotech Hunter | Biotech Hunter